Eli Lilly expands access to Zepbound and Foundayo through new partnership
1 report, 1 independent
Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Company announced an agreement to expand access to its FDA-approved medicines, Zepbound and Foundayo. Through the partnership, eligible patients can receive prescriptions for these treatments at self-pay prices via the consumer platform. Self-pay pricing for Foundayo starts at $149 per month, and Zepbound starts at $299 per month.
From prnewswire.com
Why it matters
The agreement brings Eli Lilly's obesity medicines to a large consumer platform, providing patients with a direct way to obtain the treatments at an affordable price. This move expands the market reach for Eli Lilly and Company's key GLP-1 drugs.
From prnewswire.com
Who's involved
- Eli Lilly and CompanyAmerican pharmaceutical company expanding access to Zepbound and Foundayo
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- Eli Lilly and Company acquired Point and established a supply agreement with EUZ.
- Eli Lilly and Company now owns the drugmaker AtaiBeckley.
- Eli Lilly and Merck are combining therapies in clinical trials.